Saccharomyces cerevisiae fungemia: Risk factors, outcome and links with S. boulardii-containing probiotic administration.


Journal

Infectious diseases now
ISSN: 2666-9919
Titre abrégé: Infect Dis Now
Pays: France
ID NLM: 101775152

Informations de publication

Date de publication:
May 2021
Historique:
received: 21 07 2020
revised: 01 12 2020
accepted: 04 12 2020
entrez: 3 5 2021
pubmed: 4 5 2021
medline: 27 8 2021
Statut: ppublish

Résumé

Saccharomyces cerevisiae fungemia: risk factors, outcome and links with S. boulardii-containing probiotic administration. The aim of our study was to review cases of S. cerevisiae fungemia along with the corresponding risk factors (including S. boulardii probiotic intake), treatment and outcomes. Retrospective study (2005-2017) of S. cerevisiae fungemia. All the data were extracted from medical files. We identified 10 patients with S. cerevisiae fungemia. Mean age was 59.4 years (range 21-88). Four fifths (80%) were on total parenteral or enteral nutrition, 70% had a central venous line, and 30% were admitted in an Intensive Care Unit (ICU). S. boulardii-containing probiotic prescription was identified in 6 subjects. Three patients with no risk factors such as ICU or central venous catheter were 80 years old or more. Mortality rate was 50%. S. cerevisiae fungemia is a rare but life-threatening infection, associated with intake of probiotics containing S. boulardii. Besides classical risk factors, older age should be a contraindication for these probiotics.

Identifiants

pubmed: 33934809
pii: S2666-9919(20)00025-1
doi: 10.1016/j.idnow.2020.12.003
pii:
doi:

Substances chimiques

Antifungal Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

293-295

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Auteurs

A Poncelet (A)

Infectious Diseases Department, Saint-Pierre University Hospital, Université Libre de Bruxelles, rue aux Laines, 105, 1000 Bruxelles, Belgium. Electronic address: arthur.poncelet@ulb.ac.be.

L Ruelle (L)

Infectious Diseases Department, Saint-Pierre University Hospital, Université Libre de Bruxelles, rue aux Laines, 105, 1000 Bruxelles, Belgium.

D Konopnicki (D)

Infectious Diseases Department, Saint-Pierre University Hospital, Université Libre de Bruxelles, rue aux Laines, 105, 1000 Bruxelles, Belgium.

V Y Miendje Deyi (VY)

Microbiology Department, Laboratoire Hospitalier Universitaire de Bruxelles-Universitair Laboratorium Brussel (LHUB-ULB), Brussels, Belgium.

N Dauby (N)

Infectious Diseases Department, Saint-Pierre University Hospital, Université Libre de Bruxelles, rue aux Laines, 105, 1000 Bruxelles, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH